SCHEMBL25650901

SCHEMBL25650901

COC(=O)c1nc2[nH]ccc2cc1C(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK8 P49336 4/20 0.44
▸ KDR P35968 4/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ ABL1 P00519 1/20 0.37
▸ PLK4 O00444 1/20 0.35
▸ DCLK1 O15075 1/20 0.35
▸ ROCK2 O75116 1/20 0.35
▸ PRKD3 O94806 1/20 0.35
▸ MAP4K4 O95819 1/20 0.35
▸ PAK4 O96013 1/20 0.35
▸ CHEK2 O96017 1/20 0.35
▸ INSR P06213 1/20 0.35
▸ CDK1 P06493 1/20 0.35
▸ FES P07332 1/20 0.35
▸ ROS1 P08922 1/20 0.35
▸ PDGFRB P09619 1/20 0.35
▸ PDGFRA P16234 1/20 0.35
▸ FER P16591 1/20 0.35
▸ CDK2 P24941 1/20 0.35
▸ MARK3 P27448 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24005756 0.80 CDK8 (0.47) CDK8KDRNPSR1ABL1PLK4
SCHEMBL31398541 0.79 CDK8 (0.46) CDK8NPSR1ABL1ROCK2CHEK1
SCHEMBL30452148 0.79 CDK8 (0.46) CDK8KDRNPSR1ABL1PLK4
SCHEMBL20551884 0.79 CDK8 (0.46) CDK8KDRNPSR1ABL1PLK4
SCHEMBL21751681 0.77 CDK8 (0.36) CDK8KDRABL1PLK4DCLK1
SCHEMBL25613170 0.77 CDK8 (0.44) CDK8KDRNPSR1ABL1PLK4
SCHEMBL12146427 0.73 CDK8 (0.36) CDK8KDRPLK4DCLK1ROCK2
SCHEMBL24005537 0.71 PIK3CA (0.37) CDK8KDRABL1LRRK2BRD4
SCHEMBL24005526 0.71 CDK8 (0.35) CDK8KDRPLK4DCLK1ROCK2
SCHEMBL4792436 0.71 CDK8 (0.47) CDK8KDRCHEK1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 CDK8 533/4885KDR 465/4885NPSR1 4848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback